← boardnext 2026-10-31next 2026-12-31
ANNX
Annexon, Inc.distress 4/10 · elevated risk$5.08-3%today-27% from 52w high
Lead: Geographic Atrophy
Revenue
pre-revenue
Liquidity
$175M
Runway
1.0 yrs
Shares 1y
+1%
Price & events
-27.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.0%
1D
-13.8%
1W
-3.9%
1M
-16.3%
3M
-25.1%
6M
+104.6%
1Y
-13.5%
2Y
-75.8%
5Y
-78.8%
All
Overview
- Market Cap
- $195.71M
- Volume
- 195.99K
- 52 Week Range
- $2.05 – $6.96
- Total Shares
- 38.56M
- Float Shares
- 129.36M
- Short %
- 19.30%
- % Held by Insiders
- 0.49%
- % Held by Institutions
- 102.39%
- RVOL
- 0.04x
- Beta
- 1.17
Pipeline stages · 2 programs
Vonaprument
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Tanruprubart
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-10-31 Estimated 50% readout ~2027-01-14 | Phase 3 | Vonaprument | Geographic Atrophy | — | active not recruiting |
| 2026-12-31 Estimated 50% readout ~2027-03-16 | Phase 3 | Tanruprubart | Guillain-Barre Syndrome | — | recruiting |
Catalyst news & presentations · 11
- 2026Guided 40%regulatory submissionFiled (NDA/BLA)Tanruprubart (ANX005) · EMA/FDA submissions for tanruprubartSEC 8-K
- Second Half 2026Guided 55%readoutPhase 3ANX007 · Pivotal Phase 3 ARCHER II topline data expectedSEC 8-K
- 2026Guided 40%readoutANX1502 · Update on proof-of-concept trial in CAD anticipated.SEC 8-K
- second half of 2026Guided 55%readoutPhase 3vonaprument · Topline Phase 3 ARCHER II trial data expected.SEC 8-K
- 2026-08-13earningsEarningsEarnings releaseyahoo
- March 2026conferencedata presentationsecondaryvonaprument · GA Investor Day featuring management and key opinion leaders.SEC 8-K
- second half of 2025enrollment completesecondaryPhase 3ANX007 · Phase 3 ARCHER II trial enrollment completionSEC 8-K
- first half of 2025regulatory submissionFiled (NDA/BLA)ANX005 · Planned U.S. Biologics License Application submission.SEC 8-K
- first quarter of 2025readoutANX1502 · Clinical proof of concept data expectedSEC 8-K
- August 5, 2024trial initiationsecondaryPhase 3ANX007 · Patient dosing initiated in ARCHER II global pivotal Phase 3 trialSEC 8-K
- July 18, 2024conferencedata presentationsecondaryPhase 2ANX007 · Phase 2 ARCHER data presented at ASRS Annual Scientific meetingSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $15 (+193% upside) · 8 analysts
- 2026-07-21CitizensMarket Underperform
- 2026-07-15NeedhamBuy
- 2026-05-12Goldman SachsNeutral
- 2026-03-20Chardan CapitalBuy
- 2025-12-23Chardan CapitalBuy
- 2025-12-02Clear StreetBuy
Competitors — Geographic Atrophy
Recent news
- 2026-07-21ANNX Initiates Coverage On by Citizens -- Rating Set to Market U - GuruFocus
- 2026-07-16Two New Annexon Employees Receive 10-Year Options at $6.50 - Stock Titan
- 2026-07-16Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
- 2026-07-16Annexon grants new hires options for 335,000 shares at USD 6.5 each - Bitget
- 2026-07-15Annexon (ANNX) filer Thomas Wiggans eyes 2,000-share NASDAQ stock sale - Stock Titan
- 2026-07-15Needham raises Annexon Biosciences stock price target to $25 on trial By Investing.com - Investing.com South Africa
- 2026-07-15Needham raises Annexon Biosciences stock price target to $25 on trial - Investing.com Nigeria
- 2026-07-15ANNX Maintained by Needham -- Price Target Raised to $25 - GuruFocus
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.